Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Jingxin Cao
Introduction
Jingxin Cao is a notable inventor based in Winnipeg, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant poxviruses. His work focuses on therapeutic targets for poxvirus infections and related diseases.
Latest Patents
Cao holds a patent titled "Poxvirus host range protein K3 as a positive selection marker for generation of recombinant poxviruses, a therapeutic target for poxvirus infection and a therapeutic agent for PKR related diseases." This patent describes a novel method for generating recombinant poxviruses using an E3 and K3 double deletion mutant virus as the parental virus. The method allows for crossing over between the parental virus and an insertion cassette that includes an orthopox K3 peptide and the gene of interest. Recombinant viruses are selected by infecting a host cell line that is permissive for the orthopox K3 peptide but not for the E3 and K3 double mutant parental virus. Additionally, it is demonstrated that a specific small molecule inhibitor of NEDD8 activating enzyme, MLN4924, can completely block poxvirus K3 family protein-mediated PKR degradation and virus replication.
Career Highlights
Cao is associated with Her Majesty the Queen in the Right of Canada as represented by the Minister of Health. His work in this capacity has allowed him to contribute to important advancements in health-related technologies.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Jingxin Cao's innovative work in the field of recombinant poxviruses showcases his dedication to advancing therapeutic solutions for poxvirus infections. His contributions are significant in the ongoing efforts to combat viral diseases.